Global Diabetes Prevalence in COVID-19 Patients and Contribution to COVID-19– Related Severity and Mortality: A Systematic Review and Meta-analysis

Abstract

BACKGROUND COVID-19 and diabetes both contribute to large global disease burdens. PURPOSE To quantify the prevalence of diabetes in various COVID-19 disease stages and calculate the population attributable fraction (PAF) of diabetes to COVID-19–related severity and mortality. DATA SOURCES Systematic review identified 729 studies with 29,874,938 COVID-19 patients. STUDY SELECTION Studies detailed the prevalence of diabetes in subjects with known COVID-19 diagnosis and severity. DATA EXTRACTION Study information, COVID-19 disease stages, and diabetes prevalence were extracted. DATA SYNTHESIS The pooled prevalence of diabetes in stratified COVID-19 groups was 14.7% (95% CI 12.5–16.9) among confirmed cases, 10.4% (7.6–13.6) among nonhospitalized cases, 21.4% (20.4–22.5) among hospitalized cases, 11.9% (10.2–13.7) among nonsevere cases, 28.9% (27.0–30.8) among severe cases, and 34.6% (32.8–36.5) among deceased individuals, respectively. Multivariate metaregression analysis explained 53–83% heterogeneity of the pooled prevalence. Based on a modified version of the comparative risk assessment model, we estimated that the overall PAF of diabetes was 9.5% (7.3–11.7) for the presence of severe disease in COVID-19–infected individuals and 16.8% (14.8–18.8) for COVID-19–related deaths. Subgroup analyses demonstrated that countries with high income levels, high health care access and quality index, and low diabetes disease burden had lower PAF of diabetes contributing to COVID-19 severity and death. LIMITATIONS Most studies had a high risk of bias. CONCLUSIONS The prevalence of diabetes increases with COVID-19 severity, and diabetes accounts for 9.5% of severe COVID-19 cases and 16.8% of deaths, with disparities according to country income, health care access and quality index, and diabetes disease burden.

Eliminating COVID‐19 as the immediate culprit for igniting pancreatitis

“…35 According to another study, the prevalence of newly diagnosed diabetes and hyperglycemia in individuals with COVID-19 was 5%, indicating a 1.75-fold increase compared to those without COVID-19. 36 In addition to observational research, the findings of bidirectional MR analysis conducted by Cao et al 18 indicate a potential exacerbation of COVID-19 severity by type 2 diabetes (T2D). Furthermore, the analysis reveals an elevated risk of developing T2D in individuals with severe and hospitalized cases of COVID-19.…”

Long‐term effects of coronavirus disease 2019 on diabetes complications and mortality in people with diabetes: Two cohorts in the UK and Hong Kong

“…Several studies have reported a higher prevalence of severe COVID‐19 in patients with diabetes, estimated at 9.5% by a recent meta‐analysis 2 . Further, diabetes was one of the most common co‐morbidities among hospitalized COVID‐19 patients 3,4 .…”

“…Several studies have reported a higher prevalence of severe COVID-19 in patients with diabetes, estimated at 9.5% by a recent meta-analysis. 2 Further, diabetes was one of the most common comorbidities among hospitalized COVID-19 patients. 3,4 Moreover, COVID-19-infected patients with diabetes were more probable to require intensive care unit (ICU) admission and mechanical ventilation, and develop severe complications, including acute respiratory distress syndrome and cardiac injury after COVID-19 infection.…”

Combining bioinformatics and machine learning algorithms to identify and analyze shared biomarkers and pathways in COVID-19 convalescence and diabetes mellitus

“…Many previous studies showed significant increases in the prevalence, severity, and mortality of COVID-19 in patients with DM compared to non-diabetic patients, suggesting an association of COVID-19 severity with poor glycemic control (9,10). Other studies suggested that COVID-19 may predispose infected individuals to hyperglycemia and promote the development of DM (11,12).…”